Appl. No. 09/267,511 Amdt. dated July 22, 2003 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol *in utero*, the method comprising administering to the subject while *in utero* an ADNF polypeptide in an amount sufficient to reduce the condition associated with fetal alcohol syndrome;

wherein the condition associated with fetal alcohol syndrome is selected from the group consisting of decreased body weight of the subject, decreased brain weight of the subject, decreased level of VIP mRNA of the subject, and likelihood of death of the subject in utero; and wherein the ADNF polypeptide is a member selected from the group consisting of:

- (a) an ADNF I polypeptide having the following amino acid sequence:
- (R¹)_x-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-(R²)_y (SEQ ID NO:3);
- (b) an ADNF III polypeptide having the following amino acid sequence:
- (R³)_w-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-(R⁴)_z (SEQ ID NO:4);
- (c) a mixture of the ADNF I polypeptide of part (a) and the ADNF III polypeptide of part (b);

wherein R¹, R², R³, and R⁴ are independently selected and are an amino acid sequence comprising from 1 to about 40 amino acids wherein each amino acid is independently selected; and

x, y, w, and z are independently selected and are equal to zero or one.

2-3. (Cancelled)

- 4. (Previously presented) The method of claim 1, wherein for the ADNF I polypeptide x and y are both zero.
- 5. (Previously presented) The method of claim 1, wherein for the ADNF I polypeptide:

x is one;

R¹ is Val-Leu-Gly-Gly-Gly (SEQ ID NO:5); and

Appl. No. 09/267,511 Amdt. dated July 22, 2003 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group

y is zero.

6. (Previously presented) The method of claim 1, wherein for the ADNF I polypeptide:

x is one;

R¹ is Val-Glu-Glu-Gly-Ile-Val-Leu-Gly-Gly-Gly (SEQ ID NO:6);

and

y is zero.

- 7. (Previously presented) The method of claim 1, wherein for the ADNF III polypeptide w and z are both zero.
- 8. (Previously presented) The method of claim 1, wherein for the ADNF III polypeptide:

w is one;

R³ is Gly-Gly; and

z is zero.

9. (Previously presented) The method of claim 1, wherein for the ADNF III polypeptide:

w is one;

R³ is Leu-Gly-Gly;

z is one; and

R⁴ is Gln-Ser.

10. (Previously presented) The method of claim 1, wherein for the ADNF III polypeptide:

w is one;

R³ is Leu-Gly-Leu-Gly-Gly (SEQ ID NO:7);

z is one; and

R⁴ is Gln-Ser.

11. (Previously presented) The method of claim 1, wherein for the ADNF III polypeptide:

w is one:

R³ is Ser-Val-Arg-Leu-Gly-Leu-Gly-Gly (SEQ ID NO:8);

z is one; and

Appl. No. 09/267,511 Amdt. dated July 22, 2003 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group

R⁴ is Gln-Ser.

- 12. (Previously presented) The method of claim 1, wherein the ADNF polypeptide is a mixture of ADNF I polypeptide of part (a) and the ADNF III polypeptide of part (b).
- 13. (Previously presented) The method of claim 1, wherein x, y, w, and z are all zero.
- 14. (Cancelled)
- 15. (Original) The method of claim 1, wherein the condition is a decreased body weight of the subject.
- 16. (Original) The method of claim 1, wherein the condition is a decreased brain weight of the subject.
- 17. (Original) The method of claim 1, wherein the condition is a decreased level of VIP mRNA of the subject.
- 18. (Previously presented) The method of claim 1, wherein the condition is likelihood of death of the subject *in utero*.
- 19-44. (Cancelled)
- 45. (New) The method of claim 1, wherein the ADNF polypeptide is a mixture of an ADNF I polypeptide consisting of SEQ ID NO:1 and an ADNF III polypeptide consisting of SEQ ID NO:2.
- 46. (New) The method of claim 1, wherein the ADNF polypeptide is administered before alcohol exposure.